Skip to main content
Erschienen in: Cancer Causes & Control 5/2009

01.07.2009 | Original Paper

Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study

verfasst von: Maria Dalamaga, Ilias Migdalis, Jessica L. Fargnoli, Evangelia Papadavid, Erica Bloom, Nicholas Mitsiades, Konstantinos Karmaniolas, Nicolaos Pelecanos, Sofia Tseleni-Balafouta, Amalia Dionyssiou-Asteriou, Christos S. Mantzoros

Erschienen in: Cancer Causes & Control | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Obesity and insulin resistance have been implicated in the etiology of pancreatic cancer (PC). Whether adiponectin and/or leptin, two adipocyte-secreted hormones important in metabolic regulation, are associated with PC pathogenesis and whether adiponectin receptors are expressed in PC remains unknown. In a hospital-based case–control study, we studied 81 cases with incident, histologically confirmed PC and 81 controls matched on gender and age between 2000 and 2007 to investigate the role of adiponectin and leptin adjusting for risk factors linked to PC. In a separate study, we also studied for the first time whether adiponectin receptors 1 and 2 are expressed in PC by studying 16 PC tumor tissue samples which were analyzed using immunohistochemistry. When subjects were divided into control-defined quartiles of adiponectin and leptin, lower leptin but higher adiponectin levels were associated with PC (p = 0.001 and p = 0.05 respectively) before and after controlling for age, gender, BMI, smoking status, alcohol consumption, history of diabetes, and family history of pancreatic cancer. Of the PC tumor tissue samples analyzed, 87.5% had positive or strong positive expression of AdipoR1 and 93.7% had positive or strong positive expression of AdipoR2. Further prospective studies are needed to determine whether the elevated adiponectin and low leptin levels reported in this study reflect compensatory changes during PC progression and thus can be used as markers for PC or whether they are causally implicated in PC.
Literatur
1.
Zurück zum Zitat Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMedCrossRef Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMedCrossRef
2.
Zurück zum Zitat Warshaw AL, Fernandez-del CC (1992) Pancreatic carcinoma. N Engl J Med 326:455–465PubMed Warshaw AL, Fernandez-del CC (1992) Pancreatic carcinoma. N Engl J Med 326:455–465PubMed
4.
Zurück zum Zitat Freelove R, Walling AD (2006) Pancreatic cancer: diagnosis and management. Am Fam Physician 73:485–492PubMed Freelove R, Walling AD (2006) Pancreatic cancer: diagnosis and management. Am Fam Physician 73:485–492PubMed
6.
Zurück zum Zitat Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D (1993) Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 4:375–382. doi:10.1007/BF00051341 PubMedCrossRef Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D (1993) Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 4:375–382. doi:10.​1007/​BF00051341 PubMedCrossRef
10.
Zurück zum Zitat Hanley AJ, Johnson KC, Villeneuve PJ, Mao Y (2001) Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. Int J Cancer 94:140–147. doi:10.1002/ijc.1446 PubMedCrossRef Hanley AJ, Johnson KC, Villeneuve PJ, Mao Y (2001) Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. Int J Cancer 94:140–147. doi:10.​1002/​ijc.​1446 PubMedCrossRef
12.
Zurück zum Zitat Tersmette AC, Petersen GM, Offerhaus GJ et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744PubMed Tersmette AC, Petersen GM, Offerhaus GJ et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744PubMed
13.
16.
Zurück zum Zitat Brennan AM, Mantzoros CS (2006) Drug Insight: the role of leptin in human physiology and pathophysiology–emerging clinical applications. Nat Clin Pract Endocrinol Metab 2:318–327. doi:10.1038/ncpendmet0196 PubMedCrossRef Brennan AM, Mantzoros CS (2006) Drug Insight: the role of leptin in human physiology and pathophysiology–emerging clinical applications. Nat Clin Pract Endocrinol Metab 2:318–327. doi:10.​1038/​ncpendmet0196 PubMedCrossRef
17.
Zurück zum Zitat Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007) Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86:s858–s866PubMed Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007) Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86:s858–s866PubMed
22.
Zurück zum Zitat Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007) Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 120:1573–1578. doi:10.1002/ijc.22526 PubMedCrossRef Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007) Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 120:1573–1578. doi:10.​1002/​ijc.​22526 PubMedCrossRef
23.
Zurück zum Zitat Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694PubMedCrossRef Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694PubMedCrossRef
26.
Zurück zum Zitat Dalamaga M, Nikolaidou A, Karmaniolas K et al (2007) Circulating adiponectin and leptin in relation to myelodysplastic syndrome: a case-control study. Oncology 73(1–2):26–32. doi:10.1159/000120995 PubMedCrossRef Dalamaga M, Nikolaidou A, Karmaniolas K et al (2007) Circulating adiponectin and leptin in relation to myelodysplastic syndrome: a case-control study. Oncology 73(1–2):26–32. doi:10.​1159/​000120995 PubMedCrossRef
28.
Zurück zum Zitat Greene FL, American Joint Committee on Cancer ACS (2002) AJCC cancer staging manual, 6th edn. Springer, New York, pp 157–165 Greene FL, American Joint Committee on Cancer ACS (2002) AJCC cancer staging manual, 6th edn. Springer, New York, pp 157–165
29.
Zurück zum Zitat Stolzenberg-Solomon RZ, Weinstein S, Pollak M et al (2008) Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol (in press) Stolzenberg-Solomon RZ, Weinstein S, Pollak M et al (2008) Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol (in press)
30.
Zurück zum Zitat Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J, Albanes D (2002) A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 13:417–426. doi:10.1023/A:1015729615148 PubMedCrossRef Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J, Albanes D (2002) A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 13:417–426. doi:10.​1023/​A:​1015729615148 PubMedCrossRef
31.
Zurück zum Zitat Costacou T, Zgibor JC, Evans RW et al (2005) The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh epidemiology of diabetes complications study. Diabetologia 48:41–48. doi:10.1007/s00125-004-1597-y PubMedCrossRef Costacou T, Zgibor JC, Evans RW et al (2005) The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh epidemiology of diabetes complications study. Diabetologia 48:41–48. doi:10.​1007/​s00125-004-1597-y PubMedCrossRef
32.
Zurück zum Zitat Fryzek JP, Schenk M, Kinnard M, Greenson JK, Garabrant DH (2005) The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996–1999. Am J Epidemiol 162:222–228. doi:10.1093/aje/kwi183 PubMedCrossRef Fryzek JP, Schenk M, Kinnard M, Greenson JK, Garabrant DH (2005) The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996–1999. Am J Epidemiol 162:222–228. doi:10.​1093/​aje/​kwi183 PubMedCrossRef
34.
Zurück zum Zitat Lin Y, Tamakoshi A, Kikuchi S et al (2004) Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer 110:584–588. doi:10.1002/ijc.20147 PubMedCrossRef Lin Y, Tamakoshi A, Kikuchi S et al (2004) Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer 110:584–588. doi:10.​1002/​ijc.​20147 PubMedCrossRef
40.
Zurück zum Zitat Barber MD, McMillan DC, Wallace AM, Ross JA, Preston T, Fearon KC (2004) The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer. Br J Cancer 90:1129–1132. doi:10.1038/sj.bjc.6601712 PubMedCrossRef Barber MD, McMillan DC, Wallace AM, Ross JA, Preston T, Fearon KC (2004) The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer. Br J Cancer 90:1129–1132. doi:10.​1038/​sj.​bjc.​6601712 PubMedCrossRef
Metadaten
Titel
Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study
verfasst von
Maria Dalamaga
Ilias Migdalis
Jessica L. Fargnoli
Evangelia Papadavid
Erica Bloom
Nicholas Mitsiades
Konstantinos Karmaniolas
Nicolaos Pelecanos
Sofia Tseleni-Balafouta
Amalia Dionyssiou-Asteriou
Christos S. Mantzoros
Publikationsdatum
01.07.2009
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 5/2009
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9273-z

Weitere Artikel der Ausgabe 5/2009

Cancer Causes & Control 5/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.